Clinical management of immune-related adverse events following immunotherapy treatment in patients with non-small cell lung cancer

The advent of checkpoint blockade-based immunotherapy is rapidly changing the management of lung cancer. Whereas past anticancer drugs’ primary toxicity was hematologic, the newer agents have primarily autoimmune toxicity. Thus, it is no longer enough for oncology practitioners to be skilled only in...

Descripción completa

Detalles Bibliográficos
Autores principales: Green, Hannah Elizabeth, Nieva, Jorge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8478790/
https://www.ncbi.nlm.nih.gov/pubmed/34127515
http://dx.doi.org/10.1136/jim-2021-001806

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8478790/
https://www.ncbi.nlm.nih.gov/pubmed/34127515
http://dx.doi.org/10.1136/jim-2021-001806

Ejemplares similares